Abstract The contribution of nephrotoxic medications to the development of acute kidney injury (AKI) is becoming better understood concomitant with the increased incidence of AKI in children. Treatment of AKI is not yet available, so prevention continues to be the most effective approach. There is an opportunity to mitigate severity and prevent the occurrence of AKI if children at increased risk are identified early and nephrotoxins are used judiciously. Early detection of AKI is limited by the dependence of nephrologists on serum creatinine as an indicator. Promising new biomarkers may offer early detection of AKI prior to the rise in serum creatinine. Early detection of evolving AKI is improving and offers opportunities for better management of nephrotoxins. However, the identification of patients at increased risk will remain an important first step, with a focus on the use of biomarker testing and interpretation of the results.
Introduction
The incidence of acute kidney injury (AKI) is rising, and the associated mortality in critically ill children is significant, with a 25.3 % 28-day mortality rate [1] . Preventative measures, risk stratification models, and treatment strategies need to be developed to address this significant public health problem. Patients at highest risk for developing AKI need to be identified to promote increased monitoring and minimize or eliminate exposure to potential risk factors. Among hospitalized children, nephrotoxic drug exposure is one of the most common contributors to AKI [2] and accounts for approximately 16 % of cases of AKI [3] . Critically ill patients are at the highest risk for drug-induced comorbidities of AKI, sepsis, hypotension, polypharmacy, and poor estimation of renal function [4, 5] . Unfortunately, no effective treatment for AKI is currently available, and avoidance of nephrotoxic medications is one of the few modifiable risk factors-although, the latter can be a challenge, particularly in critically ill patients. It is therefore useful to identify those children most susceptible to drugassociated AKI to determine the balance between using a medication (or combinations of medicines) with known nephrotoxic potential and delaying nephrotoxin initiation in a patient who requires the medication. Risk factors for drug-associated AKI may not be the same as those of AKI from other causes, but to date no large-scale study has addressed this question [6] . Risk factors specific to some populations are described in the literature and will be discussed in this review. We also discuss the definition of AKI, pediatric populations susceptible to drug-associated AKI, nephrotoxic medication use in terms of exposure to AKI, and ongoing research for prevention.
What is AKI?
In order to identify AKI, we first need to define it. I d e n t i f y i n g A K I b a s e d o n t h e I n t e r n a t i o n a l Classification of Diseases version 9 codes grossly underestimates the prevalence of AKI when compared to staging based on serum creatinine values [7, 8] . In 2012, in response to the need for standardized definitions for AKI, the Kidney Disease Improving Global Outcomes (KDIGO) AKI subcommittee developed a staging system for acute kidney injury (Table 1 ) [9] . This was a unifying definition, taking into account the RIFLE (Risk, Injury, Failure, Loss, End Stage) and Acute Kidney Injury Network (AKIN) criteria which had been previously used and validated [9] , as well as the pediatric RIFLE system developed for children (pRIFLE) [10] . The KDIGO criteria were ultimately developed to include those elements described in these prior staging systems, with the addition of two qualifiers: a glomerular filtration rate (GFR) of <35 mL/min/1.73 m 2 for individuals younger than 18 years or the initiation of renal support for the maximum stage of AKI [11] . The goals of defining a universal staging system for AKI include quality assurance, standardization of comparison for epidemiologic and clinical studies, and correlation of AKI with clinical outcomes such as death and dialysis [12] . The KDIGO criteria have been validated in both critically ill and non-critically ill pediatric populations to reveal that there is a stepwise increase in AKI stage with increases in length of mechanical ventilation, length of stay in hospital, cost, and mortality [13, 14] .
Limitations of serum creatinine and urine output
The current method of assessing renal function is reliant on measurements of serum creatinine and urine output. It is best to assess AKI by stage using both serum creatinine and urine output, when available, to best categorize patients for outcome stratification and management [15] . Although serum creatinine is the current standard biomarker to assess renal function, it is a suboptimal biomarker. The half-life of serum creatinine in an adult male is estimated to be 3.85 h, but it can increase to 77 h with declining renal function [16] . Given the significant adaptability and functional reserve of the kidney, serum creatinine only starts to rise when >50 % of renal functional mass has been lost [17] ; consequently it serves as a late marker for renal dysfunction. Failure to correct serum creatinine for fluid overload may also result in an underestimation of serum creatinine [18] ; thus, fluid resuscitation in critically ill patients can cause dilution of serum creatinine with subsequent inaccurate calculation of estimated GFR (eGFR) as well as inaccurate diagnosis and staging of AKI [19, 20] . Finally, with prolonged critical illness, less creatinine is produced, making it less reflective of renal function [19, 20] .
Who develops AKI?
Prior studies have shown that the prevalence of AKI ranges from 5 to 41 % depending on the definition of AKI that was used, as well as which population was being studied [21] [22] [23] . This estimated global prevalence includes both community-acquired and hospital-acquired AKI, which are sometimes difficult to differentiate. In critically ill pediatric patients who develop AKI, renal dysfunction occurs within the first 24 h of admission in about one-half of patients [24] , which often suggests community-acquired AKI. Overall, the rates of AKI, or its identification, have increased by more than ninefold between the 1980s and early 2000s [25] , and the etiology of AKI has changed from primarily intrinsic renal disease to systemic illness and nephrotoxic medication use [17, 26, 27] . Most cases of AKI are multifactorial in nature [3, 28] . Of the many known risk factors and patient-specific susceptibilities that contribute to AKI (see Table 2 ), the administration of nephrotoxic medication provides one of the few potentially modifiable risk factors if the drug in question can be removed or replaced. Incidence and risk factors for drug-associated AKI are described in a number of population sub-sets (Table 2) . Several large studies have identified that in 16-25 % of cases, nephrotoxic medication exposure is linked to the development of AKI in the adult population [29] [30] [31] . In the same population, there is a 53 % greater odds of developing AKI for each nephrotoxic medication administered to a patient [30] . In non-critically ill children exposed to three or more nephrotoxic medications or at least 3 days of intravenous aminoglycoside therapy, the incidence of AKI is reported to be 30 % [32] . Non-critically ill children who developed AKI had a significantly greater odds of exposure to at least one nephrotoxic drug, and the intensity of AKI increased with increased nephrotoxic drug exposure [2] . Conversely, increasing age can be a protective factor against developing drug-associated AKI in non-critically ill children [2] .
While these studies are insightful, there is a notable lack of standardization for identifying and grading nephrotoxic agents Aminoglycoside-associated AKI [38, 62] Non-Critically Ill Children African American race, longer treatment duration, higher baseline eGFR, treated with AG in the past month, longer hospital stays prior to starting AG, admitted under Heme/Onc service, hypoalbuminemia, concomitant use with trimethoprim/sulfamethoxazole AKI, any cause [28, 60] Non-Critically Ill Children Younger, lower weight-for-age, lower baseline serum creatinine, and higher peak serum creatinine values AKI, any cause [21, 22, 28] Critically Ill Children Younger age, (older age [21] ), higher PRISM score, presence of cardiac disease, mechanical ventilation, hypoxemia, administration of nephrotoxic medications, hypotension/need for vasopressors, coagulopathy, thrombocytopenia AKI, Acute kidney injury; CKD, chronic kidney disease; AUC, area under the curve; NSAID, non-steroidal anti-inflammatory drug; ACE-I, angiotensin converting enzyme inhibitors; GFR, glomerular filtration rate; AG, aminoglycoside; PRISM, pediatric risk of mortality [33] . Many studies use a list of nephrotoxic medications derived from formularies; some of the most commonly described nephrotoxic medications are listed in Table 3 . Several studies have used definitions of significant medication exposure as concomitant administration of three or more potentially nephrotoxic agents [32, 34] . While several medications were studied for nephrotoxic potential, the actual contribution of each medication to the development of renal dysfunction remains unclear. AKI is often multifactorial in nature, so indication bias is a major confounding variable. For example, patients with sepsis are also more likely to receive nephrotoxic medications; as such, the degree of contribution of either medication use or the underlying condition (e.g. sepsis, heart failure) to the development of AKI is often difficult to parse out.
Mechanism of drug-associated AKI
Categorizations of drug-associated AKI are based on the underlying mechanism of renal injury. Direct nephrotoxicity occurs from tubuloepithelial injury, interstitial nephritis, glomerular injury, or obstructive nephropathy, whereas indirect nephrotoxicity develops from decreased renal blood flow [4, 31] . There are pro-inflammatory processes and alterations in the renal vasculature that cause cell injury, and cellularbased changes associated with AKI have been identified and continue to be under investigation [27] . Animal models show that AKI produces a pro-inflammatory response with increased levels of inflammatory cytokines, including tumor necrosis factor and interleukins-1β, -6, and -8 [35] .
Phenotypes of drug-associated AKI
A panel of international pediatric and adult nephrologists and pharmacists have developed a standardized description of the phenotype for drug-associated kidney disease in hospitalized patients [36] . The four general categories include AKI, glomerular disorders, nephrolithiasis, and tubular dysfunction, and underlying mechanisms can either be dose-dependent or dose-independent (as in acute interstitial nephritis) [36] . The authors concede that multi-drug exposures and concurrent AKI risk factors make the use of these criteria challenging. While this phenotype-based description still requires validation, the hope is to improve the recognition of drug-associated kidney disease.
Who is at risk for drug-associated AKI?
Critical illness
Critically ill children are at increased risk for AKI from any cause and are particularly susceptible to drug-associated AKI. Studies in adults show that sepsis is the most common contributing factor for the development of AKI in critically ill patients [29] . The kidney undergoes a decrease in renal perfusion as well as an increase in exposure to inflammatory mediators in sepsis, and damage can be exacerbated by hypotension and the development of acute tubular necrosis (ATN) [20] . Vasopressers, while necessary for the management of hypotensive patients, have been identified as a risk factor for [20] and Nolin and Himmelfaub [73] IVIG, Intravenous Immunoglobulin; HAART, highly active antiretroviral therapy; AKI, acute kidney injury; NSAID, non-steroidal anti-inflammatory drug; ACE-I, angiotensin converting enzyme inhibitors AKI in critically ill adults [30] . High abdominal pressures due to injury, surgery, or ascites from poor hepatic function can cause renal vascular compression and decreased renal perfusion [20] . Not only can critical illness contribute to AKI, prolonged mechanical ventilation can be a direct effect of AKI. Selewski et al. reported that critically ill children who developed AKI were ventilated for 2.3 days longer than their counterparts who did not develop AKI and that there was a step-wise increase in the length of mechanical ventilation by AKI stage [13] . Cardiac dysfunction, which is often present concomitantly with critical illness, is discussed in a separate section of this review. Children with systemic disease may develop AKI from either multi-organ dysfunction itself, or from its treatment (use of nephrotoxic therapy) [3] . A pediatric-focused study showed that intensive care unit (ICU) patients who developed AKI were exposed to more nephrotoxic medications, with between 2.3-and 18.5-fold increased odds of developing AKI when exposed to beta-lactam antibiotics, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids [23] .
Critically ill patients have constantly fluctuating pharmacokinetics because of factors such as changing serum creatinine level and alterations in fluid status. This changing state makes medication dosing difficult and adds to the risk of AKI [20] . For critically ill adults receiving aminoglycoside therapy, there can be up to an 83 % variability in pharmacokinetics and pharmacodynamics between two successive doses of the medication [37] , and the risk for aminoglycoside-associated AKI increases in patients with hypoalbuminemia [38] . There has to be a balance between prescribing a sufficiently high medication dose to ensure an adequate concentration at the site of infection, address bacterial resistance, account for increased volume of distribution and altered protein binding while still avoiding medication toxicity and addressing altered renal clearance [5] . Critically ill patients with AKI are about 16-fold more likely to experience an adverse drug event, particularly due to changing organ function (with changing GFR), alterations in pharmacokinetics, and polypharmacy [39] .
Cardiac dysfunction
Children with cardiac dysfunction are at increased risk for renal dysfunction. Heart failure leads to decreased renal perfusion with the potential for the development of ATN, which would be exacerbated by the addition of agents that decrease renal perfusion, such as angiotensin converting enzymeinhibitors (ACE-Is), angiotensin receptor blockers (ARBs), or NSAIDs [20] . AKI often develops in children admitted with heart failure and is associated with prolonged length of stay, mortality, and need for mechanical ventilation [40] . Poor cardiac output and decreased renal blood flow may lead to fluid retention and increased systemic vascular resistance, which can in turn worsen heart failure symptoms [40] , proving that AKI is both a symptom of and contributor to other organ dysfunction. In a prospective multicenter study involving children who underwent cardiac surgery, AKI was found to occur in 42 % of patients, of whom a significant proportion had been exposed to either gentamicin or NSAIDs in the post-operative period [41] . Furosemide, which is often used as an afterload reducer in children with cardiac dysfunction, may potentiate AKI when used in conjunction with vancomycin or NSAID therapy [42, 43] .
Oncologic disease
Advances in diagnosis, treatment, and bone marrow transplantation in oncologic diseases have improved patient survival. This group of patients is at particularly high risk for AKI and long-term renal sequelae because of the advances in this field, specifically in relation to nephrotoxic exposure. In one study assessing AKI in the pediatric ICU, hemolytic uremic syndrome and hemato-oncologic pathologies represented 36 % of all cases of AKI [21] . Rapid cell breakdown, which may result from the initiation of chemotherapy in children with leukemia and lymphoma, can lead to uric acid nephropathy or crystallization of calcium phosphate in the kidney [44] . Renal injury associated with tumor lysis syndrome is associated with either blockage of the tubular lumen from crystal precipitation or alterations in renal blood flow [27] .
Nephrotic syndrome
Children who are hospitalized with nephrotic syndrome are at increased risk for AKI via multiple mechanisms, including intravascular volume depletion, infection, and exposure to potential nephrotoxic medications. A recent retrospective multicenter study showed that the incidence of AKI in children hospitalized with active nephrotic syndrome was significant, with 58.6 % of children having at least one episode of AKI during their hospital stay [45] . Exposure to nephrotoxic medications was associated with increased risk for the development of AKI. Over half of the episodes of AKI developed after admission to the hospital, and one-half of the children were given at least one nephrotoxic medication [45] , showcasing that judicious use of nephrotoxic medications may help prevent some of these episodes of AKI. ACEs and ARBs should be used with caution in patients with nephrotic syndrome since both increase the risk of AKI in those who are already intravascularly volume-depleted [26] .
Neonates
The incidence of AKI in critically ill neonates ranges from 8 to 24 % and is associated with varying mortality rates between 10 and 61 % [46] . One of the difficulties in researching neonatal AKI is the lack of a unified definition for AKI in this specific patient population. Using serum creatinine to define AKI is particularly ineffective in the neonatal period given a rapidly changing GFR during the first 2 weeks of life with alterations in renal blood flow [46] . Premature neonates are suspected to be at an even higher risk for the development of any-cause AKI given renal underdevelopment, which should encourage the limited use of nephrotoxic agents [47] . Although much remains unknown regarding specific nephrotoxic agents used in the newborn period, neonates are known to have an increased susceptibility to aminoglycosideassociated AKI [26] . Low nephron mass may lead to chronic kidney disease (CKD) later in life [46] , although the serum creatinine level may be normal in the neonatal period. Newborns who sustain AKI in the neonatal period may not develop changes in their GFR (measured by serum creatinine) until adolescence when they go through a growth spurt [48] , so ongoing renal function monitoring is important in this population.
Patients with intravascular volume depletion
It is unclear whether episodes of pre-renal azotemia are less hazardous than episodes of intrinsic AKI, and it is sometimes difficult to distinguish the two. The possibility of using tubular injury or cell-cycle arrest biomarkers in the future to help distinguish pre-renal azotemia from injury that has progressed to tubular damage is promising [19] . Medications that inhibit renal blood flow are particularly risky to use in individuals who have intravascular volume depletion.
What drugs are the biggest offenders? Antibiotics
Vancomycin and piperacillin/tazobactam, either alone or in combination, are broad-spectrum antibiotics that are commonly used for critically ill children, but they are known to have nephrotoxic potential. The nephrotoxic risk of vancomycin monotherapy has been debated since the introduction of the drug in the 1950s and has continued even after improvements in the purification procedures [49] . Vancomycin purity is currently estimated at about 95 % [50] , and nephrotoxicity is thought to be limited. However, there is evidence that vancomycin has detrimental oxidative effects on proximal tubule cells [26, 50, 51] . In three pediatric studies, 7.2-14.4 % of children who received intravenous vancomycin for >48 h developed AKI [43, 52, 53] . The authors of one study proposed that AKI occurring in critically ill children in the cardiac ICU who are receiving vancomycin was more likely to be related to the underlying illness than to be directly related to vancomycin toxicity [52] . Nephrotoxicity with vancomycin use is likely increased in children with concomitant nephrotoxic medication use [50, 51, 53] , higher mean vancomycin troughs [43, 51] , higher dose [53] , longer duration of therapy [51, 53] , or concomitant furosemide use [43] . Simultaneous use of vancomycin and piperacillin/tazobactam has been linked to the development of AKI in non-critically ill children [2] . The results of two adult studies showed that compared to vancomycin monotherapy, combination therapy of vancomycin + piperacillin/tazobactam increased the odds of hospitalized non-critically ill adult patients developing AKI by 2.48-5-fold [54, 55] , although the indication bias was difficult to control for. A more recent study showed no increased risk of AKI using this drug combination in critically ill adults [56] , suggesting that this risk may differ according to the population studied. Finally, there is even some evidence suggesting more substantial nephrotoxicity associated with piperacillin/tazobactam independent of vancomycin [2] .
Synergistic nephrotoxicity and the development of AKI with combination therapy of aminoglycosides and vancomycin is as high as 30 % in critically ill adults [31] . A study of critically ill children found that while only a number of individual medications were associated with increased risk of AKI, there was an overall increased nephrotoxic medication exposure in children who developed AKI [23] , suggesting a significant role for multiple medication exposures in the development of AKI [2] . In addition to limiting individual nephrotoxic medication use in children at high risk for AKI, it would appear to be most imperative to avoid the use of multiple nephrotoxic agents.
Aminoglycosides
While the nephrotoxic potential of aminoglycosides has been well-established, they are often necessary to treat lung infections secondary to resistant organisms in patients with cystic fibrosis. Aminoglycosides primarily cause damage to tubular epithelial cells, leading to ATN, but they can also add to renal dysfunction via activation of the the renin-angiotensin-aldosterone system and alterations of glomerular endothelial cells [27, 37] . The risk of aminoglycoside-associated AKI increases with higher peak serum levels, African American race, higher baseline renal function, longer hospital stay, longer duration of therapy, and clinical circumstances, including poor renal blood flow and concomitant nephrotoxic medication use [31] (see Table 2 ). Longer courses of aminoglycoside therapy will lead to increased cumulative exposure in the proximal tubule, thereby increasing the risk for nephrotoxicity. In one study on critically ill adults, lower GFR seemed to be a protective factor in aminoglycoside-related AKI, possibly related to the cautious use of the medication by the healthcare providers in patients with known poor kidney function [57] . Interestingly, another study found conflicting evidence: in children with cystic fibrosis receiving aminoglycoside therapy, concomitant nephrotoxic medication use was actually not associated with increased risk of AKI [38] . Regardless, it has been recommended that aminoglycosides be used with extended interval dosing to help minimize the risk of AKI [31, 37, 58] . Strategies such as inhalational use of aminoglycosides are also gaining popularity as a way to deliver medication to the site of infection while reducing systemic exposure.
Chemotherapy
Patients with malignancy, bone marrow transplant, and multivisceral and liver transplant are overrepresented in assessments of children exposed to nephrotoxic medications [8] . Several chemotherapeutic agents, including platins and methotrexate, can cause AKI [26] . Children who receive bone marrow (and solid organ) transplants are generally treated with a calcineurin-inhibitor (CNI) as a form of immunosuppression. CNIs can cause AKI via renal vasoconstriction [26] , as well as contribute to CKD from chronic use. Cyclosporin A, a (CNI) which continues to be used in the pediatric bone marrow transplant population, can also cause AKI from hemolytic uremic syndrome [26] . Children exposed to radiation via the therapeutic route or to nephrotoxic agents, including ifosfamide, methotrexate, and platins, via chemotherapy, as well as those who have undergone surgical nephrectomy should be screened for CKD since these agents are known contributors to the development of AKI [17, 27] .
Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs inhibit prostaglandin synthesis which in turn reduces renal perfusion [26, 31] . In their study of pediatric non-critically ill patients based on a search of electronic health records, Goldstein et al. found that NSAIDs were one of the only individual classes of medications that were used more often in children who developed AKI [32] . Children with acute gastroenteritis have decreased intravascular volume, and the use of NSAIDs can increase their risk for AKI by twofold, even after adjusting for degree of dehydration [59] . Misurac et al. reported that NSAIDassociated AKI accounted for 2.7 % of AKI cases in one institution and that this included a significant portion of children who took only the recommended dose [28] . All NSAID-associated AKI is not necessarily due to poor renal perfusion and/or progression to ATN, as NSAIDs can also be associated with acute interstitial nephritis. NSAID use requires careful consideration for regular administration, as often times it may be a non-essential drug selection; as such, the use of NSAIDs with other nephrotoxins requires further scrutiny [20] .
What are the consequences of AKI?
An overwhelming number of studies in both the pediatric and adult literature have shown that patients who develop AKI, from any cause, have increased hospital length of stay, increased hospital costs, and higher mortality compared to those who do not develop AKI [10, 13, 14, [21] [22] [23] [24] [60] [61] [62] . In a recent study assessing critically ill children, mortality was almost ninefold higher for children who developed AKI compared with those who did not, with a stepwise increase in mortality across KDIGO AKI stage [1] , highlighting the clear need for further research regarding prevention and treatment of this disease. While AKI is generally thought to be a result of other organ dysfunction, it likely also exacerbates the delay in recovery of other organ functions [1] .
In recent years, investigators have discovered that individual episodes of AKI affect long-term renal health. At hospital discharge, 35 % of children with a history of AKI had either decreased renal function or required continued dialysis [61] . In critically ill children with AKI and significant nephrotoxic medication exposure, up to 70 % of survivors displayed at least one sign of persistent renal dysfunction 6 months after the insult [63] . Also, in follow-up studies at 1-3 years after an AKI event, 10.3 % of patients had CKD, and almost half were at risk for CKD which manifested as slightly decreased GFR, hypertension, and/or hyperfiltration [64] . Numerous other studies have also reported similar evidence of CKD after episodes of AKI in both children [27] and adults [26] .
The effects of duration of AKI have now become more evident. Adults who have longer duration of AKI have worse long-term outcomes [15] , and critically ill children who had resolution or improvement of AKI severity had a lower mortality rate than those who had persistent AKI [1] .
What can we do once AKI is diagnosed?
Current practice aimed toward decreasing the incidence of AKI is primarily driven by prevention. Current KDIGO AKI treatment recommendations can be seen in Fig. 1 . Multiple studies have shown that the use of dopamine, which has been used to improve renal blood flow, does in fact not provide any benefit to patients with AKI as once believed [27] . We rely on diligent monitoring and withdrawal or replacement of modifiable risk factors when AKI is identified [6] . It has been shown that automatic triggers in electronic medical record systems can increase the ability to identify nephrotoxic medication exposure (particularly the use of radiocontrast) [34] . Additionally, the severity of AKI has been shown to decrease in non-critically ill children after initiation of an electronic screening trigger to encourage daily serum creatinine screening and decreased use or withdrawal of nephrotoxic medications [32] . With the increased risk of mortality in critically ill pediatric patients, studies assessing prevention strategies would be of particular importance in this young population [1] . Given the significant long-term health sequelae as described above, it is essential that children with AKI events be followed after the episode to screen for development of CKD. They also need to be monitored closely to help avoid further nephrotoxin exposure.
What's next? Biomarkers
One of the major scientific breakthroughs in AKI research has been the development of new biomarkers to aid in the prediction and early detection of AKI. If we are only using serum creatinine and/or oliguria as markers for renal injury, then AKI is being detected late. There are two major categories of promising biomarkers: tubular injury markers and cell-cycle arrest markers. In a study assessing pediatric critically ill, mechanically ventilated patients, urinary neutrophil gelatinase associated lipocalin (NGAL), a tubular injury marker, was noted to be sixfold higher in children who sustained AKI compared to controls, and this change persisted from 48 h before to 48 h after the development of AKI [65] . In drugassociated AKI, kidney injury molecule-1 (KIM-1), a tubular injury marker, has been most studied and is specific to injury in the S3 portion of the proximal renal tubule [66] . While further validation studies are necessary, microRNAs are also proving to be promising urinary biomarkers for drugassociated AKI [67] . MicroRNAs function intracellularly as post-transcriptional regulators of gene expression [68] , but they are also found extracellularly in the blood and other body fluids, including urine [67] . Deregulation of microRNA expression can be associated with organ dysfunction, including renal injury [67] . Sensitive and specific biomarkers like microRNAs could be useful for the detection of subclinical and clinical AKI as well as in drug development testing for nephrotoxicity. MicroRNAs also provide a potential future drug target for treatment of AKI [69] .
Renal angina
A BRenal Angina Index^model has been proposed as a way to help predict AKI and guide clinical evaluation, much like chest pain guides the use of troponins in patients with suspected myocardial ischemia [70] . The renal angina index includes risk factors and clinical presentation in an effort to stratify patients according to risk and to use biomarkers as effectively as possible for the detection and prediction of AKI (i.e., have a high negative predictive value for AKI) [70] . Ideally, a risk prediction tool could be implemented to detect AKI in real-time, providing clinicians with feedback on potentially modifiable risk factors [71] .
Future direction
Based on the underlying pathophysiology of AKI, possible future treatments could include anti-oxidant therapy, antiadhesion molecule therapy, or the administration of vascular mediators or mesenchymal stem cells [61] . Eventually, we may be able to assess genetic predisposition for susceptibility to particular nephrotoxic medications [6] . Ideally, widespread use of tubular injury biomarkers, cell-cycle arrest biomarkers, Fig. 1 Stage-based management of acute kidney injuryAKI (KDIGO) [9] , used with permission. Shading of boxes indicates priority of action: solid shading indicates actions that are equally appropriate at all stages whereas graded shading indicates increasing priority with increasing intensity. ICU Intensive care unit and/or microRNAs, in conjunction with a risk-stratification model could help the nephrologist to predict those patients who are going to develop AKI. This would be particularly valuable in identifying patients in whom nephrotoxic medications should be most avoided and in whom renal replacement therapy should be initiated early.
Conclusion
The morbidity, mortality, and excessive healthcare costs associated with AKI have been clearly defined, and the impetus is to prevent AKI in those children who are at high risk. Prevention of AKI will improve with earlier detection of renal injury using promising biomarkers and with the development of risk-stratification models implemented with the electronic health record. Drug-associated AKI remains an important and potentially modifiable subcategory of AKI. We need to understand which populations are at highest risk for drug-associated AKI and encourage judicious use of nephrotoxic medications and frequent monitoring in these populations, particularly when a combination of nephrotoxic agents is used. Once AKI has occurred, nephrotoxic agents should be avoided as much as possible to aid renal recovery and prevent recurrent AKI.
Key summary points
& AKI is associated with increased morbidity, mortality, and length of hospital stays in the pediatric population. & Nephrotoxic medications are one of the few potentially modifiable risk factors for AKI. & Populations at increased risk for drug-associated AKI should be monitored frequently and nephrotoxic medications should be used with caution. & With no AKI treatments available, prevention is key, and alerting systems that include biomarkers and a risk factor assessment may be beneficial.
Questions (answers are provided following the reference list) 
